Mercado de medicamentos para distúrbios do armazenamento lisossômico - Relatório de análise de tamanho, participação e tendências do mercado global - Visão geral do setor e previsão até 2032

Global Lysosomal Storage Disorder Drugs Market

Tamanho do mercado em biliões de dólares

CAGR : 9.40 %

USD 10.76 Billion USD 21.93 Billion 2024 2032

Período de previsão	2025 –2032
Tamanho do mercado (ano base )	USD 10.76 Billion
Tamanho do mercado ( Ano de previsão)	USD 21.93 Billion
CAGR	9.40 %
Principais participantes do mercado	Novartis AG Johnson &amp Johnson Private Limited Teva Pharmaceutical Industries Ltd. Merck &amp Co.Inc. Allergan Pfizer Inc. GlaxoSmithKline plc Sanofi Merck KGaA Abbott Boehringer Ingelheim International GmbH. Takeda Pharmaceutical Company Limited Amicus TherapeuticsInc. ModernaInc. Greenovation Biotech GmbH Biomarin JCR Pharmaceuticals Co.Ltd ISU ABXIS Idorsia Pharmaceuticals Ltd AVROBIOInc. Resverlogix Corp. Enzyvant CHIESI Farmaceutici SpA

Global Lysosomal Storage Disorder Drugs Market Segmentation, By Type of Disorder Gaucher DiseaseFabry DiseasePompe Disease, Mucopolysaccharidosis (MPS), Niemann-Pick DiseaseKrabbe Disease, and Others), Type (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Therapy, and Others), Drugs (Imiglucerase, Agalsidase Beta, Idursulfase, Alglucosidase Alpha, Velaglucerase, Taliglucerase Alfa, Laronidase, Agalsidase Alpha, Galsulfase, Avalglucosidase Alfa, and Others), Route of Administration (Intravenous (IV), Subcutaneous (SC), Oral, and Others), Age Group (Pediatric, Adults, and Geriatric), Gender (Male and Female), Distribution Channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies) - Industry Trends and Forecast to 2032

Lysosomal Storage Disorder Drugs Market Analysis

The global lysosomal storage disorder drugs market encompasses the commercial sector for pharmaceuticals developed to diagnose, treat, and manage various lysosomal storage disorders, which are rare genetic conditions typically characterized by the accumulation of undigested substances within lysosomes due to enzyme deficiencies. This market includes a range of therapeutic products, such as enzyme replacement therapies, substrate reduction therapies, and gene therapies, aimed at addressing the diverse clinical manifestations of LSDs, such as Gaucher disease, Fabry disease, and Pompe disease. With increasing awareness, advancements in research and technology, and a growing number of pipeline therapies, this market is poised for significant expansion. In addition, rising healthcare expenditure and initiatives to improve access to rare disease treatments further drive market growth, presenting both opportunities and challenges for pharmaceutical companies and healthcare providers.

Lysosomal Storage Disorder Drugs Market Size

Global lysosomal storage disorder drugs market size was valued at USD 10.76 billion in 2024 and is projected to reach USD 21.93 billion by 2032, growing with a CAGR of 9.4% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Lysosomal Storage Disorder Drugs Market Trends

“Biotechnology Advancements for Lysosomal Storage Disorders Treatments”

Advancements in biotechnology have played a pivotal role in transforming the treatment landscape for Lysosomal Storage Disorders (LSDs), providing patients with more effective and tailored treatment options. Enzyme Replacement Therapy (ERT) has revolutionized the treatment of Lysosomal Storage Disorders (LSDs) by directly addressing the enzyme deficiencies that cause these conditions. In LSD patients, the lack of specific enzymes leads to the accumulation of toxic substances in cells, damaging organs and tissues. ERT works by administering synthetic enzymes to compensate for the missing ones, improving metabolic functions and alleviating symptoms. Over the years, ERT has advanced significantly, with new, more effective formulations and delivery methods that improve enzyme absorption and reduce side effects. These innovations have resulted in better clinical outcomes, this trend slowed disease progression, reduced organ damage, and enhanced patient quality of life.

Report Scope and Lysosomal Storage Disorder Drugs Market Segmentation

Attributes	Lysosomal Storage Disorder Drugs Key Market Insights
Segments Covered	By Type of Disorder: Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis (MPS), Niemann-Pick Disease, Krabbe Disease, and Others By Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Therapy, and Others By Drugs: Imiglucerase, Agalsidase Beta, Idursulfase, Alglucosidase Alpha, Velaglucerase, Taliglucerase Alfa, Laronidase, Agalsidase Alpha, Galsulfase, Avalglucosidase Alfa, and Others By Route of Administration: Intravenous (IV), Subcutaneous (SC), Oral, and Others By Age Group: Pediatric, Adults, and Geriatric By Gender: Male and Female By Distribution Channel: Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies
Countries Covered	U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Denmark, Sweden, Poland, Norway, Finland, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, New Zealand, Vietnam, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Qatar, Saudi Arabia, and rest of Middle East and Africa
Key Market Players	Sanofi (France), BioMarin (U.S.), Pfizer Inc. (U.S.), Amicus Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Ultragenyx Pharmaceutical Inc. (U.S.), Orchard Therapeutics plc (U.K.), Spur Therapeutics (U.K.), Sangamo Therapeutics (U.S.), Protalix BioTherapeutics Inc. (Israel), CHIESI Farmaceutici S.p.A. (Italy), Forge Biologics (U.S.), Denali Therapeutics (U.S.), REGENXBIO INC. (U.S.), and JCR Pharmaceuticals Co., Ltd. (Japan) among others
Market Opportunities	Increasing Number of Pipeline Drugs Growing Emphasis on Early Diagnosis
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Lysosomal Storage Disorder Drugs Market Definition

Lysosomal storage disorder drugs refer to a category of pharmaceuticals specifically developed to treat Lysosomal Storage Disorders (LSDs), which are a group of rare genetic conditions caused by deficiencies in specific enzymes responsible for breaking down complex molecules within lysosomes. These drugs aim to address the underlying metabolic abnormalities associated with LSDs by either replacing the missing enzymes (enzyme replacement therapy), by enhancing the body's ability to produce the enzymes, or by modifying the substrates that accumulate due to enzyme deficiency (substrate reduction therapy). By improving enzymatic function or reducing the toxic build-up of substrates, these treatments can alleviate symptoms, slow disease progression, and ultimately improve the quality of life for individuals affected by these challenging conditions.

Lysosomal Storage Disorder Drugs Market Dynamics

Drivers

Emerging Personalized Medicine for Lysosomal Storage Disorders

Emerging personalized medicine is transforming the landscape of treatment for Lysosomal Storage Disorders (LSDs) by offering therapies specifically tailored to the individual genetic profiles of patients. LSDs are caused by genetic mutations that affect enzyme function, and these mutations can vary widely between patients. Personalized treatments involve analyzing a patient’s unique genetic makeup to develop a more targeted approach, optimizing the efficacy of therapies such as enzyme replacement or gene therapy. This precision allows for better matching of treatments with the patient's specific needs, minimizing side effects and enhancing therapeutic outcomes. As advancements in genetic testing and technology progress, healthcare providers are able to identify the most suitable interventions, potentially improving response rates and overall treatment success. The shift toward personalized medicine is accelerating the development of customized LSD treatments, which promise to revolutionize disease management. With these innovations, the global lysosomal storage disorders drug market is witnessing increased demand for more effective, individualized treatment options. Personalized medicine is thus a key driver of market growth, as it boosts treatment effectiveness and enhances patient outcomes, fostering greater confidence in therapeutic options.

For instance,

In February 2023, according to the article published by NCBI, Emerging personalized medicine uses an individual’s genetic profile to guide decisions related to the prevention, diagnosis, and treatment of diseases. This approach enables more precise and effective therapies for Lysosomal Storage Disorders (LSDs), tailoring treatments to specific genetic mutations. As personalized medicine becomes more prevalent, it drives the demand for targeted LSD therapies, fueling growth in the global lysosomal storage disorders drug market.

Increased Government Funding for Research into Rare Disease Treatments

Government funding and grants for research into rare disease treatments are crucial for advancing the development of therapies for conditions such as Lysosomal Storage Disorders (LSDs). Rare diseases, often lacking commercial viability due to small patient populations, pose significant challenges in drug development. To address this, governments worldwide are increasingly allocating funds to incentivize research in these underserved areas. Financial support in the form of grants, subsidies, and tax credits helps pharmaceutical companies and research institutions overcome the high costs and risks associated with developing treatments for rare diseases. Furthermore, governments often fast-track regulatory processes for these treatments, recognizing the urgent need for solutions. By reducing the financial burden on researchers and companies, these funding mechanisms enable the exploration of innovative therapies, such as enzyme replacement and gene therapies that would otherwise face significant barriers to development.

For instance,

In August 2023, according to the article published by National Organization for Rare Diseases, The National Organization for Rare Disorders announced over USD 100,000 in grant funding for rare disease research, highlighting increased government support for advancing treatments. These funds enable researchers to explore innovative therapies for rare diseases like Lysosomal Storage Disorders (LSDs). Such financial backing accelerates drug development, driving growth in the global LSD drug market by fostering new treatment options.

Opportunities

Increasing Number of Pipeline Drugs

The increasing number of drugs in the pipeline for Lysosomal Storage Disorders (LSDs) represents a significant opportunity for the global lysosomal storage disorders drugs market, potentially leading to improved treatment options and enhanced patient outcomes. As researchers and pharmaceutical companies enhance their understanding of these disorders, they are developing a diverse array of novel therapies, including gene therapies, substrate reduction therapies, and small molecule drugs. This expanded pipeline reflects a growing recognition of the unmet medical needs within the LSD community and promises to offer patients a wider variety of treatment modalities tailored to their specific conditions. The introduction of innovative therapies can enhance patient adherence to treatment, reduce disease burden, and ultimately improve the quality of life for individuals living with these disorders.

For instance,

In June 2024, Ultragenyx announced the Planning to file for accelerated approval of UX111 for the treatment of Sanfilippo Syndrome Type A (MPS IIIA). UX111 is a novel in vivo gene therapy in Phase 1/2/3 development for Sanfilippo syndrome type A (MPS IIIA), a rare fatal lysosomal storage disease with no approved treatment that primarily affects the central nervous system.

Growing Emphasis on Early Diagnosis

A crescente ênfase no diagnóstico precoce de distúrbios de armazenamento lisossómico (LSDs) apresenta uma oportunidade significativa para o mercado global de medicamentos para distúrbios de armazenamento lisossómico, facilitando intervenções oportunas que podem melhorar consideravelmente os resultados dos doentes. À medida que os sistemas de saúde colocam maior ênfase na detecção precoce através de melhores programas de rastreio, testes genéticos e avanços nas tecnologias de diagnóstico, é provável que mais doentes sejam diagnosticados numa fase mais precoce das suas doenças. Esta intervenção precoce permite uma melhor gestão dos sintomas, mas aumenta a eficácia potencial das terapêuticas existentes e emergentes. O resultado desta mudança é uma base de doentes mais ampla que requer e pode beneficiar de opções de tratamento, impulsionando, em última análise, a procura no mercado de medicamentos para as doenças de armazenamento lisossómico.

Por exemplo,

Em Fevereiro de 2023, de acordo com um artigo, 'Distúrbios de armazenamento lisossómico: da biologia à clínica com referência à Índia', o diagnóstico precoce é a parte mais crítica da gestão das LSDs, pois proporciona a oportunidade para intervenção terapêutica, aconselhamento genético preciso, diagnóstico pré-natal e um melhor resultado para o paciente.

Restrições/Desafios

Falta de sensibilização entre profissionais de saúde e doentes

A falta de sensibilização entre os profissionais de saúde e os doentes sobre os distúrbios de armazenamento lisossómico (LSDs) apresenta uma barreira significativa ao diagnóstico precoce, ao tratamento e à gestão eficaz. Muitos prestadores de cuidados de saúde, especialmente em regiões com exposição limitada a doenças raras, muitas vezes não conseguem reconhecer os sintomas das LSD, que são diversos e se sobrepõem a outras doenças mais comuns. Esta falta de conhecimento leva a diagnósticos tardios, erros de diagnóstico e tratamento ineficaz, agravando a gravidade da doença. Para os doentes, especialmente aqueles que vivem em áreas com poucos recursos ou mal servidas, a falta de sensibilização impede a intervenção precoce, deixando-os inconscientes de potenciais terapias. A complexidade e a raridade das LSD complicam ainda mais a situação, uma vez que os doentes e os profissionais de saúde podem não compreender totalmente a importância do tratamento precoce ou da disponibilidade de opções de cuidados especializados. Menos doentes são diagnosticados e tratados a tempo, levando a resultados clínicos abaixo do ideal. Esta falta de consciência limita a procura de tratamentos específicos para o LSD e dificulta o crescimento global do mercado global de medicamentos para as perturbações do armazenamento lisossómico.

Por exemplo,

Em janeiro de 2024, de acordo com o artigo publicado por Wiley, verifica-se um atraso significativo no diagnóstico de cerca de 15 anos desde o início dos sintomas até ao diagnóstico, o que é comum em casos de LSD em adultos devido à sobreposição de fenótipos clínicos e gravidade variável. Este atraso realça a falta de sensibilização dos profissionais de saúde, especialmente dos que tratam doentes adultos. Tais restrições dificultam a deteção precoce e o tratamento atempado, restringindo o crescimento do mercado global de medicamentos para as doenças de armazenamento lisossómico.

Procedimentos Prolongados de Aprovação de Medicamentos

Os longos processos de aprovação de medicamentos representam uma restrição significativa para o mercado global de medicamentos para distúrbios de armazenamento lisossómico, atrasando a introdução de terapias tão necessárias. O processo de obtenção de aprovação regulamentar para novos medicamentos, especialmente para doenças raras como o LSD, envolve numerosos ensaios clínicos, extensa documentação e avaliações rigorosas por parte de entidades reguladoras como a FDA e a EMA. Estes prazos de aprovação são frequentemente alargados devido à necessidade de uma avaliação completa da segurança, eficácia e potenciais efeitos a longo prazo. No caso das LSDs, a raridade e complexidade destas doenças acrescentam outra camada de desafio, uma vez que existe uma população limitada de doentes para ensaios clínicos, dificultando a geração de dados robustos. A necessidade de tratamentos especializados e a falta de normas estabelecidas para estas doenças raras complicam o processo de aprovação. Consequentemente, os criadores de medicamentos enfrentam períodos de espera prolongados, atrasos na introdução de novos tratamentos no mercado e custos adicionais, o que pode ser desencorajador para as empresas farmacêuticas. Como resultado, os longos processos de aprovação atrasam a disponibilidade de terapias inovadoras para os doentes, reduzindo o crescimento do mercado e dificultando a acessibilidade de tratamentos eficazes para os LSD. Este atraso regulamentar atua, em última análise, como uma grande restrição para o mercado global de medicamentos para distúrbios de armazenamento lisossómico.

Por exemplo,

Em agosto de 2024, de acordo com o artigo publicado pela Drugs.com, o processo de investigação, desenvolvimento e aprovação de medicamentos demora normalmente 12 a 15 anos. Este prazo alargado atrasa a introdução de novas terapêuticas e aumenta os custos para as empresas farmacêuticas. Como resultado, o longo processo de aprovação de medicamentos restringe o crescimento do mercado global de medicamentos LSD, limitando a velocidade de disponibilidade do tratamento.

Este relatório de mercado fornece detalhes dos novos desenvolvimentos recentes, regulamentos comerciais, análise de importação-exportação, análise de produção, otimização da cadeia de valor, quota de mercado, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado, análise estratégica do crescimento do mercado, tamanho do mercado, crescimento do mercado da categoria, nichos de aplicação e domínio, aprovações de produtos, lançamentos de produtos, expansões geográficas, inovações tecnológicas no mercado. Para mais informações sobre o mercado, contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a tomar uma decisão de mercado informada para alcançar o crescimento do mercado.

Escopo de mercado de medicamentos para o transtorno de armazenamento lisossómico

O mercado está segmentado com base no tipo de perturbação, tipo, medicamento, via de administração, faixa etária, sexo e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os escassos segmentos de crescimento nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.

Tipo de transtorno

Doença de Gaucher
- Tipo 1
- Tipo 3
- Tipo 2
Doença de Fabry
Doença de Pompe
- Pompa de início infantil
- Pompa de início tardio
Mucopolissacaridose (MPS)
- MPS I
- MPS II
- MPS IV
- MPS VI
- MPS III
Doença de Niemann-Pick
- Tipo C
- Tipo B
- Tipo A
Doença de Krabbe
Outros

Tipo

Terapia de substituição enzimática (TRE)
Terapia de Redução de Substratos (SRT)
Terapia de Acompanhante
Outros

Drogas

Imiglucerase
Agalsidase Beta
Idursulfase
Alglucosidase Alfa
Velaglucerase
Taliglucerase Alfa
Laronidase
Agalsidase alfa
Galsulfase
Avalglucosidase Alfa
Outros

Rota de Administração

Intravenoso (IV)
Subcutâneo (SC)
Oral
Outros

Faixa etária

Pediátrico
Adultos
Geriátrico

Género

Macho
Fêmea

Canal de Distribuição

Farmácias Hospitalares
Drogarias e farmácias de retalho
Farmácias on-line

Análise regional do mercado de medicamentos para a perturbação de armazenamento lisossómico

O mercado é analisado e os insights e tendências do tamanho do mercado são fornecidos por tipo de perturbação, tipo, medicamentos, via de administração, faixa etária, género e canal de distribuição como mencionado acima.

Os países abrangidos no mercado são os EUA, Canadá, México, Alemanha, Reino Unido, Itália, França, Espanha, Rússia, Suíça, Turquia, Bélgica, Países Baixos, Dinamarca, Suécia, Polónia, Noruega, Finlândia, resto da Europa, Japão, China , Coreia do Sul, Índia, Singapura, Tailândia, Indonésia, Malásia, Filipinas, Austrália, Nova Zelândia, Vietname, Taiwan, resto da Ásia-Pacífico, Brasil, Argentina, resto da América do Sul, África do Sul, Egipto, Bahrein, Emirados Árabes Unidos , Kuwait, Omã, Qatar, Arábia Saudita e resto do Médio Oriente e África.

Espera-se que a América do Norte domine o mercado global de medicamentos para distúrbios de armazenamento lisossómico devido à sua infraestrutura de cuidados de saúde avançada, à elevada adoção de medicamentos, aos investimentos significativos em investigação e desenvolvimento e a uma grande população de doentes.

Prevê-se que a Ásia-Pacífico seja a região com crescimento mais rápido devido ao aumento das infraestruturas de saúde, ao aumento da prevalência de doenças de armazenamento lisossomal e à crescente consciencialização sobre as terapias avançadas.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.

Participação no mercado de medicamentos para a perturbação de armazenamento lisossómico

O cenário competitivo do mercado fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.

Os líderes de mercado de medicamentos para o distúrbio de armazenamento lisossómico que operam no mercado são:

Sanofi (França)
BioMarin (EUA)
(EUA)
(EUA)
Takeda Pharmaceutical Company Limited (Japão)
(EUA)
Orchard Therapeutics plc (Reino Unido)
Spur Therapeutics (Reino Unido)
Sangamo Therapeutics (EUA)
(Israel)
Chiesi Farmaceutici SpA (Itália)
Forge Biologics (EUA)
Denali Therapeutics (EUA)
(EUA)
(Japão)

Últimos desenvolvimentos no mercado de medicamentos para distúrbios de armazenamento lisossómico

Em outubro de 2024, a Amicus Therapeutics anunciou um acordo relativo ao seu medicamento Galafold (migalastat), que trata a doença de Fabry. O acordo resolve os litígios de patentes em curso e confirma a continuação da comercialização do medicamento sem interferência judicial. Este acordo com múltiplas partes visa proporcionar estabilidade para a disponibilidade e desenvolvimento do Galafold, protegendo ao mesmo tempo os direitos de propriedade intelectual
Em junho de 2024, a Amicus Therapeutics foi homenageada com o prémio Prix Galien UK pelo seu tratamento inovador, Pombiliti (miglustat), para o tratamento da doença de Fabry. O prémio reconhece a excelência na inovação farmacêutica e enfatiza o impacto do Pombiliti na melhoria da vida dos doentes com doenças genéticas raras. Este prémio destaca a liderança da Amicus em terapias para doenças raras
Em abril de 2024, a Forge Biologics anunciou que se apresentaria nove vezes na 27ª Reunião Anual da ASGCT em maio de 2024, incluindo uma apresentação oral de última hora e três sessões técnicas. As apresentações irão cobrir o desenvolvimento de processos, avanços moleculares e atualizações clínicas, incluindo um resultado clínico significativo para o FBX-101 na doença de Krabbe
Em novembro de 2023, o Grupo Chiesi foi reacreditado como uma organização certificada como Great Place to Work em várias regiões, incluindo Itália, Austrália, EUA e outras. Com uma taxa de resposta de 85% dos colaboradores, a Chiesi alcançou uma taxa de satisfação global de 83%, refletindo o seu compromisso em promover um ambiente de trabalho positivo, inclusivo e colaborativo, focado no bem-estar e no crescimento dos colaboradores.
Em janeiro de 2024, a Denali Therapeutics Inc., uma empresa biofarmacêutica que desenvolve terapias para atravessar a barreira hematoencefálica para o tratamento de doenças neurodegenerativas e de armazenamento lisossómico, anunciou progressos e marcos para 2024. O CEO Ryan Watts, Ph.D., destacou estes desenvolvimentos durante uma apresentação corporativa na 42ª Conferência Anual JP Morgan Healthcare, a 9 de janeiro

SKU-59872

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET

1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PIPELINE ANALYSIS

5 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN NORTH AMERICA

5.2 REGULATORY AUTHORITIES IN SOUTH AMERICA

5.3 REGULATORY AUTHORITIES IN EUROPE

5.4 REGULATORY AUTHORITIES IN THE MIDDLE EAST AND AFRICA.

5.5 REGULATORY AUTHORITIES IN ASIA-PACIFIC.

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 BIOTECHNOLOGY ADVANCEMENTS FOR LYSOSOMAL STORAGE DISORDERS TREATMENTS

6.1.2 EMERGING PERSONALIZED MEDICINE FOR LYSOSOMAL STORAGE DISORDERS

6.1.3 INCREASED GOVERNMENT FUNDING FOR RESEARCH INTO RARE DISEASE TREATMENTS

6.1.4 COLLABORATIONS AND PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND RESEARCH INSTITUTIONS

6.2 RESTRAINTS

6.2.1 LACK OF AWARENESS AMONG HEALTHCARE PROFESSIONALS AND PATIENTS

6.2.2 PROLONGED DRUG APPROVAL PROCEDURES

6.3 OPPORTUNITIES

6.3.1 INCREASING NUMBER OF PIPELINE DRUGS

6.3.2 GROWING EMPHASIS ON EARLY DIAGNOSIS

6.3.3 ADVANCEMENTS IN GENE THERAPY FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS

6.4 CHALLENGES

6.4.1 SIGNIFICANT EXPENSES RELATED TO THE TREATMENT OF THE DISEASE

6.4.2 NARROW PATIENT BASE SUFFERING FROM LYSOSOMAL STORAGE DISORDERS

7 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER

7.1 OVERVIEW

7.2 GAUCHER DISEASE

7.2.1 TYPE 1

7.2.2 TYPE 3

7.2.3 TYPE 2

7.3 FABRY DISEASE

7.4 POMPE DISEASE

7.4.1 INFANTILE-ONSET POMPE

7.4.2 LATE-ONSET POMPE

7.5 MUCOPOLYSACCHARIDOSIS (MPS)

7.5.1 MPS I

7.5.2 MPS II

7.5.3 MPS IV

7.5.4 MPS VI

7.5.5 MPS III

7.6 NIEMANN-PICK DISEASE

7.6.1 TYPE C

7.6.2 TYPE B

7.6.3 TYPE A

7.7 KRABBE DISEASE

7.8 OTHERS

8 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS

8.1 OVERVIEW

8.2 IMIGLUCERASE

8.3 AGALSIDASE BETA

8.4 IDURSULFASE

8.5 ALGLUCOSIDASE ALPHA

8.6 VELAGLUCERASE

8.7 TALIGLUCERASE ALFA

8.8 LARONIDASE

8.9 AGALSIDASE ALPHA

8.1 GALSULFASE

8.11 AVALGLUCOSIDASE ALFA

8.12 OTHERS

9 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE

9.1 OVERVIEW

9.2 ENZYME REPLACEMENT THERAPY (ERT)

9.3 SUBSTRATE REDUCTION THERAPY (SRT)

9.4 CHAPERONE THERAPY

9.5 OTHERS

10 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.3 FEMALE

11 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP

11.1 OVERVIEW

11.2 PEDIATRIC

11.3 ADULT

11.4 GERIATRIC

12 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACIES

12.3 DRUGS STORES AND RETAIL PHARMACIES

12.4 ONLINE PHARMACIES

13 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 INTRAVENOUS (IV)

13.3 SUBCUTANEOUS (SC)

13.4 ORAL

13.5 OTHERS

14 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION

14.1 OVERVIEW

14.2 NORTH AMERICA

14.2.1 U.S.

14.2.2 CANADA

14.2.3 MEXICO

14.3 EUROPE

14.3.1 GERMANY

14.3.2 UNITED KINGDOM

14.3.3 FRANCE

14.3.4 ITALY

14.3.5 SPAIN

14.3.6 RUSSIA

14.3.7 SWITZERLAND

14.3.8 TURKEY

14.3.9 BELGIUM

14.3.10 NETHERLANDS

14.3.11 DENMARK

14.3.12 SWEDEN

14.3.13 POLAND

14.3.14 NORWAY

14.3.15 FINLAND

14.3.16 REST OF EUROPE

14.4 ASIA-PACIFIC

14.4.1 CHINA

14.4.2 JAPAN

14.4.3 INDIA

14.4.4 SOUTH KOREA

14.4.5 AUSTRALIA

14.4.6 THAILAND

14.4.7 SINGAPORE

14.4.8 INDONESIA

14.4.9 MALAYSIA

14.4.10 PHILIPPINES

14.4.11 TAIWAN

14.4.12 NEW ZEALAND

14.4.13 VIETNAM

14.4.14 REST OF ASIA-PACIFIC

14.5 MIDDLE EAST AND AFRICA

14.5.1 SAUDI ARABIA

14.5.2 UNITED ARAB EMIRATES (UAE)

14.5.3 SOUTH AFRICA

14.5.4 EGYPT

14.5.5 QATAR

14.5.6 KUWAIT

14.5.7 OMAN

14.5.8 BAHRAIN

14.5.9 REST OF MIDDLE EAST AND AFRICA

14.6 SOUTH AMERICA

14.6.1 BRAZIL

14.6.2 ARGENTINA

14.6.3 REST OF SOUTH AMERICA

15 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 SANOFI

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 BIOMARIN

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 PFIZER INC.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 AMICUS THERAPEUTIC, INC.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 CHIESI FARMACEUTICI S.P.A.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 DENALI THERAPEUTICS

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PIPELINE PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 FORGE BIOLOGICS

17.8.1 COMPANY SNAPSHOT

17.8.2 PIPELINE PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

17.9 JCR PHARMACEUTICALS CO., LTD.

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PINELINE PRODUCT PORTFOLIO

17.9.4 PRODUCT PORTFOLIO

17.9.5 RECENT DEVELOPMENT

17.1 ORCHARD THERAPEUTICS PLC

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 PROTALIX BIOTHERAPEUTICS

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PIPELINE PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 REGENXBIO INC.

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PINELINE PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENT

17.13 SANGAMO THERAPEUTICS

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 SPUR THERAPEUTICS

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 ULTRAGENYX PHARMACEUTICAL INC.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Lista de Tabela

TABLE 1 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 2 GLOBAL GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 3 GLOBAL GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 4 GLOBAL FABRY DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 5 GLOBAL POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 6 GLOBAL POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 7 GLOBAL MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 8 GLOBAL MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 9 GLOBAL NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 10 GLOBAL NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 11 GLOBAL KRABBE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 12 GLOBAL OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 13 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 14 GLOBAL IMIGLUCERASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 15 GLOBAL AGALSIDASE BETA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 16 GLOBAL IDURSULFASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 17 GLOBAL ALGLUCOSIDASE ALPHA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 18 GLOBAL VELAGLUCERASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 19 GLOBAL TALIGLUCERASE ALFA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 20 GLOBAL LARONIDASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 21 GLOBAL AGALSIDASE ALPHA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 22 GLOBAL GALSULFASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 23 GLOBAL AVALGLUCOSIDASE ALFA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 24 GLOBAL OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 25 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 26 GLOBAL ENZYME REPLACEMENT THERAPY (ERT) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 27 GLOBAL SUBSTRATE REDUCTION THERAPY (SRT) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 28 GLOBAL CHAPERONE THERAPY IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 29 GLOBAL OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 30 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 31 GLOBAL MALE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 32 GLOBAL FEMALE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 33 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 34 GLOBAL PEDIATRIC IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 35 GLOBAL ADULT IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 36 GLOBAL GERIATRIC IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 37 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 38 GLOBAL HOSPITAL PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 39 GLOBAL DRUGS STORES AND RETAIL PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 40 GLOBAL ONLINE PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 41 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 42 GLOBAL INTRAVENOUS (IV) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 43 GLOBAL SUBCUTANEOUS (SC) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 44 GLOBAL ORAL IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 45 GLOBAL OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 46 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 47 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 48 NORTH AMERICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 49 NORTH AMERICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 50 NORTH AMERICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 51 NORTH AMERICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 52 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 53 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 54 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 55 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 56 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 57 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 58 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 59 U.S. GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 60 U.S. POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 61 U.S. MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 62 U.S. NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 63 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 64 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 65 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 66 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 67 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 68 U.S. LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 69 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 70 CANADA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 71 CANADA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 72 CANADA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 73 CANADA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 74 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 75 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 76 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 77 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 78 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 79 CANADA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 80 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 81 MEXICO GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 82 MEXICO POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 83 MEXICO MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 84 MEXICO NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 85 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 86 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 87 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 88 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 89 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 90 MEXICO LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 91 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 92 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 93 EUROPE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 94 EUROPE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 95 EUROPE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 96 EUROPE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 97 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 98 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 99 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 100 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 101 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 102 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 103 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 104 GERMANY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 105 GERMANY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 106 GERMANY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 107 GERMANY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 108 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 109 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 110 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 111 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 112 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 113 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 114 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 115 UNITED KINGDOM GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 116 UNITED KINGDOM POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 117 UNITED KINGDOM MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 118 UNITED KINGDOM NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 119 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 120 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 121 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 122 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 123 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 124 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 125 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 126 FRANCE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 127 FRANCE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 128 FRANCE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 129 FRANCE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 130 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 131 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 132 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 133 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 134 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 135 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 136 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 137 ITALY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 138 ITALY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 139 ITALY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 140 ITALY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 141 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 142 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 143 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 144 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 145 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 146 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 147 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 148 SPAIN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 149 SPAIN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 150 SPAIN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 151 SPAIN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 152 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 153 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 154 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 155 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 156 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 157 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 158 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 159 RUSSIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 160 RUSSIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 161 RUSSIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 162 RUSSIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 163 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 164 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 165 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 166 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 167 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 168 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 169 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 170 SWITZERLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 171 SWITZERLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 172 SWITZERLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 173 SWITZERLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 174 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 175 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 176 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 177 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 178 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 179 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 180 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 181 TURKEY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 182 TURKEY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 183 TURKEY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 184 TURKEY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 185 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 186 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 187 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 188 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 189 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 190 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 191 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 192 BELGIUM GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 193 BELGIUM POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 194 BELGIUM MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 195 BELGIUM NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 196 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 197 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 198 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 199 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 200 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 201 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 202 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 203 NETHERLANDS GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 204 NETHERLANDS POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 205 NETHERLANDS MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 206 NETHERLANDS NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 207 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 208 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 209 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 210 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 211 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 212 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 213 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 214 DENMARK GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 215 DENMARK POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 216 DENMARK MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 217 DENMARK NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 218 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 219 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 220 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 221 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 222 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 223 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 224 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 225 SWEDEN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 226 SWEDEN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 227 SWEDEN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 228 SWEDEN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 229 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 230 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 231 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 232 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 233 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 234 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 235 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 236 POLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 237 POLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 238 POLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 239 POLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 240 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 241 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 242 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 243 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 244 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 245 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 246 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 247 NORWAY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 248 NORWAY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 249 NORWAY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 250 NORWAY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 251 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 252 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 253 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 254 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 255 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 256 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 257 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 258 FINLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 259 FINLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 260 FINLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 261 FINLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 262 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 263 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 264 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 265 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 266 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 267 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 268 REST OF EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 269 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 270 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 271 ASIA-PACIFIC GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 272 ASIA-PACIFIC POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 273 ASIA-PACIFIC MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 274 ASIA-PACIFIC NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 275 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 276 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 277 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 278 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 279 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 280 ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 281 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 282 CHINA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 283 CHINA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 284 CHINA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 285 CHINA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 286 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 287 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 288 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 289 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 290 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 291 CHINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 292 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 293 JAPAN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 294 JAPAN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 295 JAPAN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 296 JAPAN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 297 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 298 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 299 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 300 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 301 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 302 JAPAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 303 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 304 INDIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 305 INDIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 306 INDIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 307 INDIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 308 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 309 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 310 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 311 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 312 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 313 INDIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 314 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 315 SOUTH KOREA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 316 SOUTH KOREA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 317 SOUTH KOREA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 318 SOUTH KOREA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 319 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 320 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 321 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 322 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 323 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 324 SOUTH KOREA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 325 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 326 AUSTRALIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 327 AUSTRALIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 328 AUSTRALIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 329 AUSTRALIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 330 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 331 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 332 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 333 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 334 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 335 AUSTRALIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 336 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 337 THAILAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 338 THAILAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 339 THAILAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 340 THAILAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 341 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 342 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 343 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 344 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 345 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 346 THAILAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 347 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 348 SINGAPORE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 349 SINGAPORE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 350 SINGAPORE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 351 SINGAPORE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 352 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 353 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 354 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 355 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 356 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 357 SINGAPORE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 358 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 359 INDONESIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 360 INDONESIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 361 INDONESIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 362 INDONESIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 363 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 364 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 365 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 366 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 367 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 368 INDONESIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 369 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 370 MALAYSIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 371 MALAYSIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 372 MALAYSIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 373 MALAYSIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 374 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 375 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 376 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 377 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 378 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 379 MALAYSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 380 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 381 PHILIPPINES GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 382 PHILIPPINES POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 383 PHILIPPINES MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 384 PHILIPPINES NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 385 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 386 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 387 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 388 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 389 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 390 PHILIPPINES LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 391 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 392 TAIWAN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 393 TAIWAN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 394 TAIWAN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 395 TAIWAN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 396 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 397 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 398 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 399 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 400 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 401 TAIWAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 402 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 403 NEW ZEALAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 404 NEW ZEALAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 405 NEW ZEALAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 406 NEW ZEALAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 407 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 408 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 409 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 410 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 411 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 412 NEW ZEALAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 413 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 414 VIETNAM GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 415 VIETNAM POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 416 VIETNAM MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 417 VIETNAM NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 418 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 419 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 420 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 421 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 422 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 423 VIETNAM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 424 REST OF ASIA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 425 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 426 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 427 MIDDLE EAST AND AFRICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 428 MIDDLE EAST AND AFRICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 429 MIDDLE EAST AND AFRICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 430 MIDDLE EAST AND AFRICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 431 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 432 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 433 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 434 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 435 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 436 MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 437 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 438 SAUDI ARABIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 439 SAUDI ARABIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 440 SAUDI ARABIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 441 SAUDI ARABIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 442 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 443 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 444 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 445 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 446 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 447 SAUDI ARABIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 448 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 449 UNITED ARAB EMIRATES (UAE) GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 450 UNITED ARAB EMIRATES (UAE) POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 451 UNITED ARAB EMIRATES (UAE) MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 452 UNITED ARAB EMIRATES (UAE) NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 453 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 454 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 455 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 456 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 457 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 458 UNITED ARAB EMIRATES (UAE) LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 459 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 460 SOUTH AFRICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 461 SOUTH AFRICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 462 SOUTH AFRICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 463 SOUTH AFRICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 464 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 465 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 466 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 467 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 468 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 469 SOUTH AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 470 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 471 EGYPT GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 472 EGYPT POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 473 EGYPT MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 474 EGYPT NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 475 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 476 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 477 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 478 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 479 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 480 EGYPT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 481 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 482 QATAR GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 483 QATAR POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 484 QATAR MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 485 QATAR NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 486 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 487 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 488 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 489 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 490 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 491 QATAR LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 492 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 493 KUWAIT GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 494 KUWAIT POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 495 KUWAIT MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 496 KUWAIT NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 497 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 498 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 499 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 500 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 501 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 502 KUWAIT LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 503 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 504 OMAN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 505 OMAN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 506 OMAN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 507 OMAN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 508 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 509 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 510 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 511 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 512 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 513 OMAN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 514 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 515 BAHRAIN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 516 BAHRAIN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 517 BAHRAIN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 518 BAHRAIN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 519 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 520 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 521 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 522 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 523 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 524 BAHRAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 525 REST OF MIDDLE EAST AND AFRICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 526 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 527 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 528 SOUTH AMERICA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 529 SOUTH AMERICA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 530 SOUTH AMERICA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 531 SOUTH AMERICA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 532 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 533 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 534 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 535 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 536 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 537 SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 538 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 539 BRAZIL GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 540 BRAZIL POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 541 BRAZIL MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 542 BRAZIL NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 543 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 544 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 545 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 546 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 547 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 548 BRAZIL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 549 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

TABLE 550 ARGENTINA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 551 ARGENTINA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 552 ARGENTINA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 553 ARGENTINA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 554 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 555 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 556 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 557 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 558 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)

TABLE 559 ARGENTINA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 560 REST OF SOUTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)

Lista de Figura

FIGURE 1 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SEGMENTATION

FIGURE 2 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SEGMENTATION

FIGURE 10 EXECUTIVE SUMMARY

FIGURE 11 SEVEN SEGMENTS COMPRISE THE GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER

FIGURE 12 STRATEGIC DECISIONS

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LYSOSOMAL STORAGE DISORDER MARKET AND ASIA PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 BIOTECHNOLOGY ADVANCEMENTS FOR LYSOSOMAL STORAGE DISORDER TREATMENTS IS EXPECTED TO DRIVE THE GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET IN THE FORECAST PERIOD

FIGURE 15 GAUCHER DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET IN 2025 & 2032

FIGURE 16 ASIA PACIFIC IS THE FASTEST GROWING MARKET FOR THE GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET

FIGURE 17 PESTEL ANALYSIS

FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET

FIGURE 19 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, 2024

FIGURE 20 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, 2025-2032 (USD MILLION)

FIGURE 21 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, CAGR (2025-2032)

FIGURE 22 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, LIFELINE CURVE

FIGURE 23 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, 2024

FIGURE 24 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, 2025-2032 (USD MILLION)

FIGURE 25 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, CAGR (2025-2032)

FIGURE 26 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 27 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, 2024

FIGURE 28 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, 2025-2032 (USD MILLION)

FIGURE 29 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, CAGR (2025-2032)

FIGURE 30 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 31 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, 2024

FIGURE 32 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, 2025-2032 (USD MILLION)

FIGURE 33 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 34 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 35 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, 2024

FIGURE 36 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, 2025-2032 (USD MILLION)

FIGURE 37 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, CAGR (2025-2032)

FIGURE 38 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 39 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 40 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)

FIGURE 41 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 42 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2024

FIGURE 44 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)

FIGURE 45 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)

FIGURE 46 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 47 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SNAPSHOT 2024

FIGURE 48 GLOBAL LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

FIGURE 49 NORTH AMERICA LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

FIGURE 50 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

FIGURE 51 AISA-PACIFIC LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

Quais são os principais segmentos abordados no relatório Global Lysosomal Storage Disorder Drugs Market?

O mercado é segmentado com base em Segmentation, By Type of Disorder Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis (MPS), Niemann-Pick Disease, Krabbe Disease, and Others), Type (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Therapy, and Others), Drugs (Imiglucerase, Agalsidase Beta, Idursulfase, Alglucosidase Alpha, Velaglucerase, Taliglucerase Alfa, Laronidase, Agalsidase Alpha, Galsulfase, Avalglucosidase Alfa, and Others), Route of Administration (Intravenous (IV), Subcutaneous (SC), Oral, and Others), Age Group (Pediatric, Adults, and Geriatric), Gender (Male and Female), Distribution Channel  (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies) - Industry Trends and Forecast to 2032 .

Qual é o tamanho atual do mercado de Global Lysosomal Storage Disorder Drugs Market?

O tamanho do Global Lysosomal Storage Disorder Drugs Market foi avaliado em USD 10.76 USD Billion no ano de 2024.

Qual é a taxa de crescimento esperada para Global Lysosomal Storage Disorder Drugs Market?

O Global Lysosomal Storage Disorder Drugs Market está projetado para crescer a um CAGR de 9.4% durante o período de previsão de 2025 a 2032.

Quem são os principais players do Global Lysosomal Storage Disorder Drugs Market?

Os principais players do mercado incluem ,Novartis AG Johnson &amp, Johnson Private Limited Teva Pharmaceutical Industries Ltd. Merck &amp, Co.Inc. Allergan Pfizer Inc. GlaxoSmithKline plc Sanofi Merck KGaA Abbott Boehringer Ingelheim International GmbH. Takeda Pharmaceutical Company Limited Amicus TherapeuticsInc. ModernaInc. Greenovation Biotech GmbH Biomarin JCR Pharmaceuticals Co.Ltd ISU ABXIS Idorsia Pharmaceuticals Ltd AVROBIOInc. Resverlogix Corp. Enzyvant CHIESI Farmaceutici SpA ,.

Quais países são analisados no relatório Global Lysosomal Storage Disorder Drugs Market?

O relatório de mercado cobre dados de U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Denmark, Sweden, Poland, Norway, Finland, rest of Europe, Japan, China, South Korea,  India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, New Zealand, Vietnam, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Qatar, Saudi Arabia, and rest of Middle East and Africa.

Global Lysosomal Storage Disorder Drugs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

Global Lysosomal Storage Disorder Drugs Market

CAGR : 9.40 %

Lysosomal Storage Disorder Drugs Market Analysis

Lysosomal Storage Disorder Drugs Market Size

Escopo de mercado de medicamentos para o transtorno de armazenamento lisossómico

Análise regional do mercado de medicamentos para a perturbação de armazenamento lisossómico

Participação no mercado de medicamentos para a perturbação de armazenamento lisossómico

Últimos desenvolvimentos no mercado de medicamentos para distúrbios de armazenamento lisossómico

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Relatórios

Informações de mercado

Apoiar

Soluções

Global Lysosomal Storage Disorder Drugs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

Global Lysosomal Storage Disorder Drugs Market

CAGR : 9.40 %

Lysosomal Storage Disorder Drugs Market Analysis

Lysosomal Storage Disorder Drugs Market Size

Escopo de mercado de medicamentos para o transtorno de armazenamento lisossómico

Análise regional do mercado de medicamentos para a perturbação de armazenamento lisossómico

Participação no mercado de medicamentos para a perturbação de armazenamento lisossómico

Últimos desenvolvimentos no mercado de medicamentos para distúrbios de armazenamento lisossómico

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas